6-Fluorobicyclo[3.1.0]hexane Derivatives

专利摘要:
The present invention provides an antidepressant comprising as an active ingredient a compound having group II metabolic glutamic acid receptor antagonism, and 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2 represented by the following formula (I): 6-dicarboxylic acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof. <Formula I> In formula, R <1> and R <2> is the same or different, shows a hydroxy, a C 1-10 alkoxy group, etc., R <3> is a C 1-10 acyl group, a C 1-6 alkoxy C 1-6 acyl group R 4 and R 5 are the same or different and represent a hydrogen atom, a C 1-10 alkyl group, or the like.
公开号:KR20040068348A
申请号:KR10-2004-7010069
申请日:2002-12-26
公开日:2004-07-30
发明作者:아츠로 나까자또；시게유끼 자끼；가즈나리 사까가미；료꼬 데안；히로시 오따；시호 히로따；아끼또 야스하라
申请人:다이쇼 세이야꾸 가부시끼가이샤；
IPC主号:

专利说明:

6-fluorobicyclo [3.1.0] hexane derivatives {6-Fluorobicyclo [3.1.0] hexane Derivatives}
[3] Recently, as cloning of glutamic acid receptor genes continues, it has been found that there are an amazing number of subtypes of glutamic acid receptors. Currently, glutamic acid receptors are broadly classified into two types: "ionotropic types in which the receptor has an ion channel structure" and "metabolism in which the receptor is conjugated with G-protein" (Science, 258 , 597-). 603, 1992). In addition, the ionotropic receptor is pharmacologically N-methyl-D-aspartic acid (NMDA), α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) and kainate (Science, 258 , 597-603, 1992) and metabolic receptors are classified into eight types, type 1 to type 8 (J. Neurosci., 13 , 1372-1378, 1993: Neuropharmacol. , 34, 1-26, 1995).
[4] Metabolic glutamic acid receptors are also pharmacologically classified into three groups. Among them, group II (mGluR2 / mGluR3) binds with adenylcyclase and inhibits the accumulation of forskolin-stimulating cyclic adenosine monophosphate (cAMP) (Trends Pharmacol. Sci., 14 , 13 (1993) )), Compounds antagonizing group II metabolic glutamic acid receptors are believed to be effective in the treatment or prevention of acute and chronic psychiatric and neurological diseases.
[5] The present invention relates to the treatment and prevention of psychiatric disorders such as ataxia (schizophrenia), anxiety and related disorders, bipolar disorder, epilepsy, and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, and muscle stiffness. A drug having therapeutic and prophylactic effects of neurological diseases such as exercise disorders, cerebral ischemia, brain failure, spinal cord disorders, and head disorders, and aims to provide a drug that antagonizes group II metabolic glutamic acid receptors.
[6] In addition, as antidepressants, serotonin reuptake inhibitors (SSRIs) and noradrenaline reuptake inhibitors and the like are known, but these are not generated based on the cause of the onset. For this reason, patients who do not exhibit the effects of these drugs still suffer from depressive diseases and are forced to inadequate daily life. Therefore, on the basis of the cause of the onset, the creation of a drug acting on the basis of the depressive symptoms is desired.
[7] It is an object of the present invention to provide a new type of antidepressant which is also effective in the treatment and prevention of depressive symptoms in which existing drugs do not work effectively.
[1] The present invention relates to 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivatives useful as medicaments. More specifically, integrated ataxia (schizophrenia), anxiety and related disorders, bipolar disorder, psychiatric disorders such as epilepsy, and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, and exercise according to muscular rigidity Novel 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarl for the treatment and prevention of neurological diseases such as disorders, cerebral ischemia, brain failure, spinal cord disorders, and head disorders It relates to an acid derivative.
[2] The present invention also relates to the compounds acting as antagonists of mGluR2 and mGluR3 belonging to subgroup II of the metabolic active (metabotropic) glutamic acid receptor (mGluR) exert a therapeutic and prophylactic effect of depressive symptoms.
[92] 1 and 2 show that rats administered the known group II metabolic glutamic acid receptor antagonist LY341495 (Journal of Medicinal Chemistry 1998, 41, 358-378) and compound 34 of the present invention, respectively, were used to evaluate antidepressant action. It is a graph measuring the dead time when swimming.
[8] <Start of invention>
[9] The present inventors conducted intensive studies on 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivatives and found that they have an antagonistic action on group II metabolic glutamic acid receptors. A novel 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative was detected and a compound having group II metabolic glutamic acid receptor antagonism was tested. Through animal experiments, it was found that this kind of compound is very effective for the treatment of depressive symptoms.
[10] In other words, the present invention provides an antidepressant comprising a compound having group II metabolic glutamic acid receptor antagonism as an active ingredient, and a novel 2-amino-3-alkoxy-6-fluorobicyclo having an antagonistic activity at group II metabolic glutamic acid receptor [ 3.1.0] hexane-2,6-dicarboxylic acid derivatives.
[11] One aspect of the present invention is an antidepressant comprising a compound having group II metabolic glutamic acid receptor antagonism as an active ingredient.
[12] In addition, one of the embodiments of the present invention is a 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative represented by the following general formula (I): Salts or their hydrates.
[13]
[14] Wherein R ¹ and R ² are the same or different and are a C _1-6 alkoxy group substituted with hydroxy, a C _1-10 alkoxy group, a phenoxy group, a naphthyloxy group, one or two phenyl groups, C _{1 -6} alkoxyC _1-6 alkoxy group, hydroxyC _2-6 alkoxy group, amino group, amino group substituted by one or two C _1-6 alkyl groups same or different, one or two identical or different Amino group substituted by C _1-6 alkoxyC _1-6 alkyl group, amino group substituted by one or two hydroxyC _2-6 alkyl groups, identical or different, one or two C _1- same or different Amino group substituted by ₆ alkoxycarbonylC _1-6 alkyl group, or NR ⁶ -CHR ⁷ -A-CO ₂ R ⁸ , wherein R ⁶ and R ⁷ are the same or different and are a hydrogen atom, hydroxy C _1-6 alkyl group, a hydroxy-carbonyl C _1-6 alkyl group, a C _1-10 alkyl group, a phenyl group, a phenyl C _1-6 alkyl group, a hydroxy Fe Group, a hydroxyphenyl-C _1-6 alkyl group, a naphthyl group, a naphthyl C _1-6 alkyl group, an aromatic heterocyclic C _1-6 alkyl, C _1-6 alkoxy C _1-6 alkyl, amino C _2-6 alkyl group, a sphere Or anininoC _2-6 alkyl group, mercaptoC _2-6 alkyl group, C _1-6 alkylthioC _1-6 alkyl group, aminocarbonylC _1-6 alkyl group, or R ⁶ and R ⁷ It may represent a group which forms a methylene group, an ethylene group, or a propylene group, may mutually combine, and may form a cyclic amino group, R <^8> represents a protecting group of a hydrogen atom or a carboxyl group, A represents a single bond, a methylene group, an ethylene group, or a propylene group Represents a natural or non-natural amino acid residue represented by
[15] R ³ is C _1-10 acyl group, C _1-6 alkoxyC _1-6 acyl group, hydroxyC _2-10 acyl group, C _1-6 alkoxycarbonylC _1-6 acyl group, hydroxycarbonyl C An amino acid residue represented by _1-6 acyl group or R ⁹ -NH-A-CHR ⁷ -CO (wherein R ⁷ and A have the same meaning as described above and R ⁹ represents a protecting group of a hydrogen atom or an amino group) Indicate,
[16] R ⁴ and R ⁵ are the same or different and a 5-membered heteroaromatic ring containing one or more hydrogen atoms, a C _1-10 alkyl group, a C _2-10 alkenyl group, a phenyl group, a naphthyl group, a hetero atom, or a halogen atom Substituted with 1 to 5 substituents selected from the group consisting of C _1-10 alkyl, C _1-10 alkoxy, trifluoromethyl, phenyl, hydroxycarbonyl, amino, nitro, cyano and phenoxy groups It may represent a phenyl group, or R ⁴ and R ⁵ may be bonded to each other to form a cyclic structure.
[17] The terms used in the present invention are defined below.
[18] C _1-10 alkoxy group refers to a straight or branched chain alkoxy group having 1 to 10 carbon atoms, for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, t -Butoxy group, pentyloxy group, isopentyloxy group, etc .;
[19] A C _1-6 alkoxy group substituted with one or two phenyl groups is a straight chain having 1 to 6 carbon atoms substituted with one or two phenyl groups, or a branched alkyl group having 3 to 6 carbon atoms. And benzyl group, diphenylmethyl group, 1-phenylethyl group, 2-phenylethyl group, and the like.
[20] C _1-6 alkoxyC _1-6 alkoxy group refers to a C _1-6 alkoxy group substituted with a C _1-6 alkoxy group, for example, a methoxyethoxy group, an ethoxyethoxy group, a propoxyethoxy group, iso Propoxyoxy group, butoxyethoxy group, isobutoxyethoxy group, t-butoxyethoxy group, pentyloxyethoxy group, isopentyloxyethoxy group, methoxypropoxy group, ethoxypropoxy group , Propoxypropoxy, isopropoxy propoxy, butoxypropoxy, isobutoxypropoxy, t-butoxypropoxy, pentyloxypropoxy, isopentyloxypropoxy and the like.
[21] The hydroxyC _2-6 alkoxy group refers to a C _2-6 alkoxy group substituted with one or more hydroxyl groups, for example, a 2-hydroxyethoxy group, 3-hydroxypropoxy group, 2,3-di Hydroxypropoxy group and the like.
[22] An amino group substituted by the same or different 1 or 2 C _1-6 alkyl groups is, for example, an N-methylamino group, an N, N-diethylamino group, an N-butyl-N-isopropylamino group, or the like.
[23] Amino groups substituted by the same or different one or two C _1-6 alkoxyC _1-6 alkyl groups are, for example, N-3-methoxypropylamino groups, N, N-bis (2-ethoxybutyl) Amino group, N- (2-butoxyethyl) -N- (1-ethoxypropyl) amino group and the like.
[24] An amino group substituted by one or two hydroxyC _2-6 alkyl groups same or different is, for example, an N-4-hydroxybutylamino group, a N, N-bis (3-hydroxypentyl) amino group, N And-(2-hydroxyethyl) -N- (1-hydroxypentyl) amino group.
[25] An amino group substituted by one or two C _1-6 alkoxycarbonylC _1-6 alkyl groups which are the same or different is, for example, an N- (3-ethoxycarbonylpropyl) amino group, N, N-bis ( 2-methoxycarbonylethyl) amino group, N- (3-propoxycarbonylpropyl) -N- (2-methoxybutyl) amino group, and the like.
[26] The hydroxy C _1-6 alkyl group refers to a C _1-6 alkyl group substituted by one or more hydroxyl groups, for example, a hydroxymethyl group, 1-hydroxyethyl, 2-hydroxyethyl group, 3-hydroxyphene And a methyl group and 2-hydroxy-2-methylbutyl group.
[27] The hydroxycarbonyl C _1-6 alkyl group represents a C _1-6 alkyl group substituted by one or more hydroxycarbonyl groups, for example, hydroxycarbonylmethyl, 4-hydroxycarbonylbutyl group, 2-hydroxy Carbonylethyl group, 3-hydroxycarbonylpropyl group and the like.
[28] A C _1-10 alkyl group is a straight chain having 1 to 10 carbon atoms, a branched chain having 3 to 10 carbon atoms, or a cyclic alkyl group having 3 to 10 carbon atoms, and examples of the linear alkyl group include, for example, For example, a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group, and a decyl group, As a branched alkyl group, for example, isopropyl group, isobutyl group, t-butyl group , Isopentyl group, 1-ethylpropyl group, isohexyl group, 2-ethylbutyl group, isoheptyl group, isooctyl group, isononyl group, isodecyl group, cyclopropylmethyl group, 2- (cyclopropyl) ethyl group, cyclobutyl As a cyclic alkyl group, a methyl group, a cyclopentyl methyl group, etc. are mentioned, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, etc. are mentioned.
[29] A phenylC _1-6 alkyl group is, for example, benzyl, 2-phenylethyl group, 2-phenylpropyl group, 1-methyl-2-phenylpentyl group and the like.
[30] The hydroxyphenyl C _1-6 alkyl group is, for example, 4-hydroxybenzyl group, 2- (4-hydroxyphenyl) ethyl group, 3- (4-hydroxyphenyl) propyl group, 4- (4-hydroxy Phenyl) butyl group and the like.
[31] The naphthyl C _1-6 alkyl group is, for example, 1-naphthylmethyl group, 2-naphthylmethyl group, 2- (1-naphthyl) ethyl group, 2- (2-naphthyl) ethyl group, or the like.
[32] An aromatic heterocyclic C _1-6 alkyl group represents the C _1-6 alkyl group which aromatic heterocyclic rings, such as an indole ring or an imidazole ring, couple | bonded, for example, an indol-3-ylmethyl group, the 1H- imidazol-4-ylmethyl group And so on.
[33] C _1-6 alkoxyC _1-6 alkyl group refers to a C _1-6 alkyl group substituted with one or more C _1-6 alkoxy groups, for example, 2-methoxyethyl group, 3-ethoxypentyl group, 3- A propoxybutyl group.
[34] The amino C _2-6 alkyl group is, for example, 2-aminoethyl group, 3-aminopropyl group, 4-aminobutyl group, 5-aminopentyl group, 6-aminohexyl group, or the like.
[35] Guanidino C _2-6 alkyl group is, for example, 2-guanidinoethyl group, 3-guanidinopropyl group, 4-guanidinobutyl group, 5-guanidinopentyl group, 6-guanidinohex It is a practical skill.
[36] The mercaptoC _2-6 alkyl group is, for example, a mercaptomethyl group, a 2-mercaptoethyl group, a 3-mercaptopropyl group, and the like.
[37] C _1-6 alkylthioC _1-6 alkyl group is methylthiomethyl group, 2-methylthioethyl group, 3-methylthiopropyl group, 4-methylthiobutyl group, 5-methylthiopentyl group, 6-methylthiohexyl group And so on.
[38] The aminocarbonyl C _1-6 alkyl group refers to a C _1-6 alkyl group substituted with one or more aminocarbonyl groups, for example, an aminocarbonylmethyl group, 2-aminocarbonylethyl group, 2-aminocarbonylpropyl group, 4-aminocarbonylbutyl group etc.
[39] The protecting group of the carboxyl group is, for example, a C _1-10 alkyl group, a phenylC _1-6 alkyl group, a nitrobenzyl group, a methoxybenzyl group and the like (E. Wuensch, "Synthese von Peptiden" in "Houben-Weyl Methoden der Organishen Chemie "Vol. XV / 1, 2. and E. Gross. J. Meienhofer," The Peptides "vol. 1 to Vol. 5).
[40] The C _1-6 acyl group represents a straight or branched acyl group having 1 to 10 carbon atoms, for example, a formyl group, an acetyl group, a 1-methylpropanoyl group, a hexanoyl group, or the like.
[41] C _1-6 alkoxy C _1-6 acyl group refers to an acyl group of C _1-6 substituted by 1 or more C _1-6 alkoxy groups dog, for example ethoxy noilgi butanone, 3-isopropoxy-penta noilgi to 3, 4-ethoxyhexanoyl group.
[42] The hydroxy C _2-10 acyl group represents a C _2-10 acyl group substituted with one or more hydroxyl groups, and examples thereof include 4-hydroxybutanoyl group and 2- (hydroxymethyl) butanoyl group.
[43] The C _1-6 alkoxycarbonylC _1-6 acyl group is, for example, 3-methoxycarbonylpropanoyl group, 4-ethoxycarbonylbutanoyl group and the like.
[44] The hydroxycarbonyl C _1-6 acyl group is, for example, 3-hydroxycarbonyl-2-methylbutanoyl group, 5-hydroxycarbonylpropanoyl group and the like.
[45] The protecting group of the amino group is, for example, a C _1-10 acyl group, a C _1-6 alkoxy C _1-6 acyl group, benzyloxycarbonyl group, nitrobenzyloxycarbonyl group, methoxybenzyloxycarbonyl group, or the like (E. Wuensch, "Synthese" von Peptiden "in" Houben-Weyl Methoden der Organishen Chemie "Vol. XV / 1, 2. and E. Gross. J. Meienhofer," The Peptides "vol. 1 to Vol. 5).
[46] A C _2-10 alkenyl group is a straight chain having 2 to 10 carbon atoms having at least one double bond, a branched chain having 3 to 10 carbon atoms, or having 5 to 10 carbon atoms. Cyclic alkenyl group is shown and it is 2-propenyl group, 1-methyl- 2-pentenyl group, 2-pentenyl group, 2-methyl- 2-hexenyl group, 2-cyclopentenyl group, etc., for example.
[47] Five-membered heteroaromatic rings containing at least one hetero atom are the same or different and represent an aromatic five-membered ring having at least one hetero atom in the ring, for example thiophene, pyrrole, furan, pyrazole, isoxazole , Isothiazole, imidazole, oxazole, thiazole, oxadiazole, thiadiazole and the like.
[48] Natural or non-natural amino acid residues are, for example, glycine, alanine, varine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, histidine, serine, threonine, cysteine, methionine, aspartic acid, asparagine, glutamic acid, glutamine, Residues such as lysine, ornithine, and arginine, and natural amino acid residues are preferred.
[49] 1 to 5 substituents selected from the group consisting of halogen atoms, C _1-10 alkyl groups, C _1-10 alkoxy groups, trifluoromethyl groups, phenyl groups, hydroxycarbonyl groups, amino groups, nitro groups, cyano groups and phenoxy groups A substituted phenyl group is a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a C _1-10 alkyl group, a cyclic C _3-10 alkyl group, a C _1-10 alkoxy group, a cyclic C _3-10 alkoxy group, a trifluoromethyl group, A phenyl group substituted with 1 to 5 substituents selected from a phenyl group, a hydroxycarbonyl group, an amino group, a nitro group, a cyano group, or a phenoxy group, for example, a 2-fluorophenyl group, 3 -Fluorophenyl group, 4-fluorophenyl group, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2-bromophenyl group, 3-bromophenyl group, 4-bromophenyl group, 2-iodinephenyl group, 3 Iodinephenyl group, 4-iodinephenyl group, 2- Tylphenyl group, 3-methylphenyl group, 4-methylphenyl group, 2-ethylphenyl group, 3-ethylphenyl group, 4-ethylphenyl group, 2-isopropylphenyl group, 3-isopropylphenyl group, 4-isopropylphenyl group, 2-cyclopropyl Phenyl group, 3-cyclopropylphenyl group, 4-cyclopropylphenyl group, 2-cyclohexylphenyl group, 3-cyclohexylphenyl group, 4-cyclohexylphenyl group, 2-methoxyphenyl group, 3-methoxyphenyl group, 4-methoxyphenyl group, 2-isopropoxyphenyl group, 3-isopropoxyphenyl group, 4-isopropoxyphenyl group, 2-cyclobutyloxyphenyl group, 3-cyclobutyloxyphenyl group, 4-cyclobutyloxyphenyl group, 2-cyclohexyloxyphenyl group, 3 -Cyclohexyloxyphenyl group, 4-cyclohexyloxyphenyl group, 2-trifluoromethylphenyl group, 3-fluoromethylphenyl group, 4-trifluoromethylphenyl group, 2-phenylphenyl group, 3-phenylphenyl group, 4-phenylphenyl group , 2-hydroxycarbonylphenyl group, 3-hydroxycarbonylphenyl group, 4-hydroxycarbonyl pe Nyl group, 2-aminophenyl group, 3-aminophenyl group, 4-aminophenyl group, 2-nitrophenyl group, 3-nitrophenyl group, 4-nitrophenyl group, 2-cyanophenyl group, 3-cyanophenyl group, 4-cyanophenyl group, 2-phenoxyphenyl group, 3-phenoxyphenyl group, 4-phenoxyphenyl group, etc., For example, as a phenyl group substituted with two substituents, a 2, 3- difluoro phenyl group, a 2, 4- difluoro phenyl group, 2 , 5-difluorophenyl group, 2,6-difluorophenyl group, 3,4-difluorophenyl group, 3,5-difluorophenyl group, 2,3-dichlorophenyl group, 2,4-dichlorophenyl group, 2 , 5-dichlorophenyl group, 2,6-dichlorophenyl group, 3,4-dichlorophenyl group, 3,5-dichlorophenyl group, 2,3-dibromophenyl group, 2,4-dibromophenyl group, 2,5-di Bromophenyl group, 2,6-dibromophenyl group, 3,4-dibromophenyl group, 3,5-dibromophenyl group, 2,3-diiodinephenyl group, 2,4-diiodinephenyl group, 2,5 -Diiodinephenyl group, 2,6-diiodinephenyl group, 3,4-diiodinephenyl group, 3,5-diiodine Phenyl group, 3-chloro-4-fluorophenyl group, 4-chloro-3-fluorophenyl group, 3-bromo-4-fluorophenyl group, 4-bromo-3-fluorophenyl group, 4-bromo-3 -Chlorophenyl group, 3-bromo-4-chlorophenyl group, 3-chloro-4-methylphenyl group, 4-chloro-3-methylphenyl group, 3-fluoro-4-methylphenyl group, 4-fluoro-3-methylphenyl Group, 3-fluoro-4-methoxyphenyl group, 4-fluoro-3-methoxyphenyl group, 3-bromo-4-methoxyphenyl group, 4-bromo-3-methoxyphenyl group, 3-chloro- 4-phenoxyphenyl group, 4-chloro-3-phenoxyphenyl group, 3-chloro-4-nitrophenyl group, 4-chloro-3-nitrophenyl group, 4-bromo-3-nitrophenyl group, 3-bromo-4 -Nitrophenyl group, 3-amino-4-bromophenyl group, 4-amino-3-bromophenyl group, 3-bromo-4-hydroxycarbonyl group, 4-bromo-3-hydroxycarbonylphenyl group, 4- Fluoro-3-hydroxycarbonyl group, 3-fluoro-4-hydroxycarbonylphenyl group, 4-fluoro-3-hydroxycarbono Nyl group, 3-cyano-4-fluorophenyl group, 3-cyano-4-fluorophenyl group, 4-cyano-3-methylphenyl group, 3-cyano-4-methylphenyl group, 3-cyano-4 -Methoxyphenyl group, 4-cyano-3-methoxyphenyl group, etc., for example, as a phenyl group substituted with three substituents, a 2,3,4-trifluorophenyl group and a 3,4,5-trifluorophenyl group , 3,4,5-trichlorophenyl group, 3,5-dichloro-4-methoxyphenyl group or 3,5-dibromo-4-methoxyphenyl group. For example, a phenyl group substituted with four substituents includes a 2,5-dibromo-3,4-dimethoxyphenyl group, a 3,4-dibromo-2,5-dimethoxyphenyl group and the like. For example, the phenyl group substituted with five substituents is a 2,3,4,5,6-pentafluorophenyl group.
[50] The form in which R <^4> and R <^5> mutually couple | bonds and forms a cyclic structure is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, a cyclopentenyl group, and a cyclohexyl group, for example. Senyl group, cycloheptenyl group, cyclooctenyl group, oxacyclobutyl group, oxacyclopentyl group, oxcyclohexyl group, oxacycloheptyl group, oxacyclooctyl group, azacyclobutyl group, azacyclopentyl group, azacyclohexyl group And an azacycloheptyl group and an azacyclooctyl group.
[51] In addition, the pharmaceutically acceptable salt in this invention is organic salts, such as salt with inorganic acids, such as sulfuric acid, hydrochloric acid, and phosphoric acid, acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, etc. Salts with acids, salts with amines such as trimethylamine and methylamine, or salts with metal ions such as sodium ions, potassium ions and calcium ions.
[52] Five subtitle carbon atoms are present in the bicyclo [3.1.0] hexane ring of the compound represented by the formula (I). Preferred steric solids of the present invention are optically active agents having an absolute structure represented by the formulas (II) and (III), but may exist as enantiomer mixtures such as enantiomers, racemates, and the like. That is, the compound of the present invention includes all of the enantiomeric mixtures and diastereomer mixtures, such as optically active compounds and racemates, of the compounds represented by the following formulas (II) and (III).
[53]
[54]
[55] In addition, the compounds of the present invention may exist as solvates of water or organic solvents.
[56] In addition, when one or both of R ¹ and R ² in formula (I), (II) or (III) represent something other than hydroxy, or R ³ represents something other than a hydrogen atom, ie ester derivatives and amide derivatives are group II metabolic glutamic acid receptors Does not affect However, the ester derivatives and amide derivatives are hydrolyzed in vivo, affecting the group II metabolic glutamic acid receptors, 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6- To dicarboxylic acid derivatives. Thus, ester derivatives and amide derivatives are very useful compounds because they function as prodrugs.
[57] The compound of the present invention represented by the formula (I) is supplied by the production method shown below (in the following scheme, R ¹ , R ² , R ³ , R ⁴ , R ⁵ , R ⁶ , R ⁷ , R ⁸ and R ⁹ Is the same meaning as described above, R ¹⁰ represents an aryl and alkylsulfonyl group, benzoyl group or 4-nitrobenzoyl group such as a mesyl group, a phenylsulfonyl group, a tosyl group, a trifluoromethylsulfonyl group, etc. R ¹¹ , R ¹² , R ¹³ and R ¹⁴ are the same or different, and C _1-10 alkoxy group, a phenoxy group, naphthyloxy group, one or two phenyl group substituted with a C _1-6 alkoxy group, a C _1-6 alkoxy C _{1- 6} alkoxy group or hydroxyC _2-6 alkoxy group R ¹⁵ represents the same amino group, one or two hydrogen atoms substituted by the same or different C _1-6 alkyl groups, one or two hydrogen atoms Or an amino group substituted by different C _1-6 alkoxyC _1-6 alkyl groups, one or two hydrogens Amino groups substituted by the same or different hydroxyC _2-6 alkyl groups, one or two hydrogen atoms substituted by the same or different C _1-6 alkoxycarbonylC _1-6 alkyl groups, or NR ⁶ − CHR ⁷ -A-CO ₂ R ⁸ ).
[58] First, the synthetic intermediate (6) necessary for synthesizing the compound [I] of the present invention can be produced as follows.
[59]
[60] Step 1: Compound (1) in an inert solvent in the presence of a base, for example, trifluoromethanesulfonylating agent such as trifluoromethanesulfonic anhydride and N-phenyl-bis (trifluoromethanesulfonimide); It can be led to compound (2) by making it react. Here, as an inert solvent, For example, hydrocarbon solvents, such as benzene, toluene, hexane, halogen solvents, such as dichloromethane, chloroform, carbon tetrachloride, ether, such as tetrahydrofuran, diethyl ether, and 1, 2- dimethoxyethane Solvents, acetonitrile, mixed solvents thereof, and the like can be used. Examples of the base include amines such as triethylamine, N-methylmorpholine, diisopropylethylamine and pyridine, inorganic bases such as potassium hydride and sodium hydride, lithium diisopropylamide and potassium bis (trimethylsilyl) amide. And metal amides such as metal amides such as lithium hexamethyldisilazane, sodium methoxide and potassium t-butoxide.
[61] Step 2: Compound (2) in an inert solvent in the presence of a transition metal catalyst, for example, organic bases such as triethylamine, N-methylmorpholine, diisopropylethylamine, pyridine, potassium carbonate, sodium hydrogencarbonate and the like It can be derived from compound (3) by reacting with carbon monoxide and R ² OH in the presence of inorganic bases of (see Tetrahedron Letters 26 , 1109 (1985)). The transition metal catalyst is, for example, a zero-valent palladium reagent, for example, divalent palladium such as palladium acetate (II), triphenylphosphine, 2,2'-bis (diphenylphosphino) -1,1 It can be manufactured in a reaction system using a ligand such as BINAP. In addition, zero-valent palladium reagents, such as tetrakistriphenylphosphine palladium (0), can also be used directly. Examples of the inert solvent include hydrocarbon solvents such as benzene, toluene and hexane, ether solvents such as tetrahydrofuran, diethyl ether and 1,2-dimethoxyethane, acetonitrile, N, N-dimethylformamide, Or a mixed solvent thereof.
[62] Step 3: General diolation reaction using Compound (3) in an inert solvent, for example, osmium tetraoxide or the like (see M. Hudlicky, "Oxidations in 0rganic Chemistry"), or Sharpless, using AD-mix as a reagent. See subtitle cis-dihydroxylation reaction (Sharpless AD) (Tetrahedron Asymmetry 4 , 133 (1993), J. 0rg. Chem. 57 , 2768 (1992), J. 0rg. Chem. 61, 2582 (1996)). Or the like to obtain a compound (4). Here, as an inert solvent, For example, alcohol solvents, such as t-butyl alcohol, hydrocarbon solvents, such as benzene, toluene, and hexane, ether-types, such as tetrahydrofuran, diethyl ether, and 1, 2- dimethoxyethane, A solvent, acetonitrile, acetone, N, N-dimethylformamide, water, or a mixed solvent thereof can be used.
[63] Step 4: Compound (4) is, for example, a hydrocarbon solvent such as benzene, toluene, hexane, a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride, tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane Organic bases such as triethylamine, N-methylmorpholine, diisopropylethylamine, pyridine, or inert solvents such as ether solvents, acetonitrile, or a mixed solvent thereof, or potassium carbonate, sodium hydrogencarbonate, etc. After reacting with thionyl chloride in the presence or absence of an inorganic base, a hydrocarbon solvent such as benzene, toluene, hexane, a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride, tetrahydrofuran, diethyl ether, 1,2 Hydrogen peroxide, oxone, ruthenium trimethium-methacrylate in an inert solvent such as ether solvent such as dimethoxyethane, acetonitrile, acetone, water, or a mixed solvent thereof. It can be induced into compound (5) by oxidation with a common oxidizing agent such as sodium iodate (see M. Hudlicky, "Oxidations in 0rganic Chemistry").
[64] Step 5: Sodium azide in compound (5) in an inert solvent such as ether solvents such as tetrahydrofuran, ketones such as acetone, N, N-dimethylformamide, water, or a mixed solvent thereof And then hydrolyzed to lead to compound (6) (see J. Am. Chem. Soc. 110 , 7538 (1988)).
[65] The synthetic intermediate (9) necessary for synthesizing the compound of the present invention having the relative stereochemical configuration represented by the formula (III) can be prepared from the compound (7) having the relative configuration shown below in the synthetic intermediate (6) as follows. Can be.
[66]
[67] Step 6: R ¹ and hydrocarbon solvents such as R ² is a hydroxy of the compound (7) other than hydroxy, for example benzene, toluene, hexane, cyclohexane, dichloromethane, halogen-based solvents such as chloroform, carbon tetrachloride, etc. Ether solvents such as tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, amides such as N, N-dimethylformamide and N-methyl-2-pyrrolidinone, dimethyl sulfoxide, or these Inorganic bases such as sodium hydride, potassium hydride, potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, metal amides such as lithium bis (trimethylsilyl) amide, lithium diisopropylamide, sodium amide, and the like in an inert solvent such as , Bases such as organic bases such as triethylamine, pyridine, diisopropylethylamine, 4- (N, N-dimethylamino) pyridine, 2,6-di-t-butylpyridine and potassium t-butoxide Trifluoromethane under Trifluoromethanesulfonylating agents such as phosphonic anhydride and N-phenyl-bis (trifluoromethanesulfonimide), or alkyl and arylsulfonylating agents such as methanesulfonyl chloride, benzenesulfonyl chloride and toluenesulfonyl chloride It can lead to compound (8) by reaction with.
[68] Step 7: Compound (8) is, for example, a hydrocarbon solvent such as benzene, toluene, hexane, cyclohexane, a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride, tetrahydrofuran, diethyl ether, 1,2- Ether solvents such as dimethoxyethane, amides such as N, N-dimethylformamide and N-methyl-2-pyrrolidinone, alcohol solvents such as dimethyl sulfoxide, methanol and ethanol, water or mixed solvents thereof Alkali hydroxides such as potassium hydroxide, sodium hydroxide, nitrites such as potassium nitrite (see Tetrahedron Lett., 3183 (1975)) and potassium oxide (Tetrahedron Lett. 34, 8029) in the presence or absence of crown ethers in an inert solvent such as And (9) to intermediate (9).
[69] Furthermore, the compound (7) is obtained by Mitsunobu reaction (see DL Hughes, OR, 42, 335 (1992)) with a benzoic acid derivative in the presence of a dehydrating condensing agent such as diethyl azodicarboxylic acid and triphenylphosphine. Can also be derived directly from compound (9).
[70] The obtained synthetic intermediate (6) can be derived from compound [I], which is a compound of the present invention, according to the following steps 8, 9 and 10.
[71]
[72] Step 8: Hydroxy solvents such as benzene, toluene, hexane, cyclohexane, halogen solvents such as dichloromethane, chloroform, carbon tetrachloride, and the like of hydroxy of compound (6) in which R ¹ and R ² are other than hydroxy Bronsted, such as trifluoromethanesulfonic acid, trifluoroacetic acid, or hydrogen chloride, in an inert solvent such as an ether solvent such as tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, or a mixed solvent thereof. X is 2,2,2-trichloroacetimidoyl jade in the presence of a Lewis acid catalyst such as an acid catalyst, boron trifluoride-diethyl ether complex, zinc chloride, tin chloride, or trimethylsilyl-trifluoromethanesulfonate It can be induced to compound (10) by reacting with a compound represented by the formula R ⁴ R ⁵ CHX (see J. Chem. Soc. Perkin Trans. 1, 2247 (1985), Synthesis, 568 (1987)).
[73] In addition, the hydroxy of the compound (6) in which R ¹ and R ² are other than hydroxy is, for example, a hydrocarbon solvent such as benzene, toluene, hexane, a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride, tetrahydrofuran Ether solvents such as diethyl ether, 1,2-dimethoxyethane, amides such as N, N-dimethylformamide, N-methyl-2-pyrrolidinone, dimethyl sulfoxide, mixed solvents thereof, and the like. Inorganic bases such as sodium hydride, potassium hydride, potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, metal amides such as lithium bis (trimethylsilyl) amide, lithium diisopropylamide, sodium amide, and triethylamine in an inert solvent of , In the presence of a base such as diisopropylethylamine, 4- (N, N-dimethylamino) pyridine, 2,6-di-t-butylpyridine, or a base such as potassium t-butoxide, X is 2, , 2,2-trichloroacetimidoyloxy It can also be led to compound (10) by reacting with a compound represented by the formula R ⁴ R ⁵ CHX other than the group. X is a leaving group and is a halogen atom, a tosyl sulfonate, a trifluoromethane sulfonate, a trill sulfonate, etc. here.
[74] Step 9: The compound (10) is, for example, a hydrocarbon solvent such as benzene, toluene or hexane, a halogen solvent such as dichloromethane, chloroform or carbon tetrachloride, tetrahydrofuran, diethyl ether or 1,2-dimethoxyethane. Staudinger reaction with triethyl phosphite, trimethylphosphine, tributylphosphine, triphenylphosphine or the like in an inert solvent such as an ether solvent, acetonitrile, acetone, water, or a mixed solvent thereof. Bull. Chem. Soc. Fr., 815 (1985)), alcohols such as ethanol and methanol, esters such as ethyl acetate, inert solvents such as N, N-dimethylformamide, water, or a mixed solvent thereof Reduction reaction of general azide groups represented by hydrogenation in the presence of metal catalysts such as palladium / carbon, palladium black, and hydride reduction by lithium aminoborohydride and the like (AF Abdel-Magid, "Reduct ions in Organic Synthesis ") to compounds (11) of the present invention.
[75] Step 10: The moieties represented by the formulas COR ¹ and COR ² of the compound (11) are converted into carboxylic acids by general hydrolysis reaction (see TW Greene, PGM Wuts, “Protective Groups in Organic Synthesis”). It can lead to compound (I) which is a compound of invention.
[76] Compounds (13) and (l4) of the present invention which are monoester derivatives and monoamide derivatives can be derived from compounds (11) or (12) according to the following steps 11 and 12.
[77]
[78] Step 11: The part represented by the formula COR ¹ of compound (11) is converted into carboxylic acid by a general hydrolysis reaction (see TW Greene, PGM Wuts, “Protective Groups in Organic Synthesis”) at a short time or at low temperature. It can be derived from the compound (13) of the invention.
[79] Step 12: The carboxylic acid on the 6-position carbon of compound (12) is subjected to general esterification reaction (see TW Greene, PGM Wuts, “Protective Groups in Organic Synthesis”), or a compound represented by R ¹⁵ -H and a general amino acid Compounds of the Invention (14) by producing an ester or amide bond by a peptide bond production reaction (see E. Gross. J. Meienhofer, “The Peptides” and JP Greenstein, M. Witntz, “Chemistry of the Amino Acids”) Can be induced.
[80] The following processes 13, 14, 15, 16, 17 and 18 can lead to amide derivatives (17) and (22) from compound (15) or compound (18).
[81]
[82] Process 13: The amino group of the compound (15), for example, hydrocarbon solvents such as benzene, toluene, hexane, halogen solvents such as dichloromethane, chloroform, carbon tetrachloride, tetrahydrofuran, diethyl ether, 1,2-dime Triethylamine, pyridine, in an inert solvent such as ether solvents such as oxyethane, amides such as N, N-dimethylformamide, N-methyl-2-pyrrolidinone, dimethyl sulfoxide, or a mixed solvent thereof; In the presence or absence of organic bases such as morpholine, diisopropylethylamine, 4- (N, N-dimethylamino) pyridine, 2,6-di-t-butylpyridine, formula R ³ X or formula R ³ OR Reaction with the compound represented by ³ can lead to compound (16). X is a leaving group here, for example, is a halogen atom, an ethoxycarbonyloxy group, a phenoxycarbonyloxy group, etc. In addition, general amide bond formation reactions with compounds represented by the formula R ³ OH (E. Gross. J. Meienhofer, “The Peptides” and JP Greenstein, M. Witntz, “Chemistry of the Amino Acids”, Vol. 2. It can also lead to compound (16).
[83] Step 14: Refer to the general deprotection reaction (TW Greene, PGM Wuts, “Protective Groups in Organic Synthesis”) for the ester moiety of compound (16) and the protecting group R ⁷ of the amino group of compound (16), wherein R ³ is of the formula COCHR ⁶ NHR ⁷ . ) Can be converted into a carboxylic acid and an amino group to lead to a 2-amide derivative (17).
[84] Step 15: The ester linkage on the 6 position carbon of compound (18) can be derived to compound (19) by general hydrolysis reaction (see TW Greene, PGM Wuts, “Protective Groups in Organic Synthesis”) at a short or low temperature. have.
[85] Process 16: The carboxylic acid moiety of the compound (19) is subjected to the peptide bond formation reaction of the compound represented by the general formula R ¹⁵ -H with a general amino acid (E. Gross. J. Meienhofer, “The Peptides” and JP Greenstein, M. Witntz, “Chemistry of the Amino Acids” can be derived from compound (20).
[86] Step 17: The compound (20) is, for example, a hydrocarbon solvent such as benzene, toluene or hexane, a halogen solvent such as dichloromethane, chloroform or carbon tetrachloride, tetrahydrofuran, diethyl ether or 1,2-dimethoxyethane. Staudinger reaction with triethyl phosphite, trimethylphosphine, tributylphosphine, triphenylphosphine or the like in an inert solvent such as ether solvent, acetonitrile, acetone, water, or a mixed solvent thereof. Bull. Chem. Soc. Fr., 815 (1985)), alcohols such as ethanol and methanol, esters such as ethyl acetate, inert solvents such as N, N-dimethylformamide, water, or a mixed solvent thereof Reduction reaction of general azide groups represented by hydrogenation in the presence of metal catalysts such as palladium / carbon, palladium black, and hydride reduction by lithium aminoborohydride and the like (AF Abdel-Magid "Reduct) ions in Organic Synthesis ").
[87] Step 18: The ester linkage of Compound (21) can be derived into Compound (22) of the present invention by general hydrolysis reaction (see T. W. Greene, P. G. M. Wuts, “Protective Groups in Organic Synthesis”).
[88] In the present invention, a compound having group II metabolic glutamic acid receptor antagonism is used as a cell expressing mGluR2 and mGluR3, respectively. Pharmacol., 53, 228-233, 1998 ”shows a concentration-dependent inhibitory action in receptor binding experiments, and shows affinity equal to or greater than glutamic acid in affinity for mGluR2 / R3, and the amount of cAMP Refers to a compound that antagonizes the forskolin-stimulated cAMP increasing inhibitory action of glutamic acid when measured by the cAMP measurement kit. Alternatively, the compound antagonizes glutamic acid-induced GTPγS binding as measured by GTPγS binding.
[89] The compounds of the present invention may be made into a pharmaceutical formulation in combination with one or two or more pharmaceutically acceptable carriers, excipients and diluents. Examples of the carrier, excipient, and diluent include water, lactose, dextrose, fructose, sucrose, sorbitol, mannitol, polyethylene glycol, propylene glycol, starch, gum, gelatin, arginate, calcium silicate, and phosphoric acid. And various oils such as calcium, cellulose, water syrup, methyl cellulose, polyvinylpyrrolidone, alkyl parahydroxybenzoate, talc, magnesium stearate, stearic acid, glycerin, sesame oil, olive oil and soybean oil.
[90] The compounds of the present invention are further mixed with these carriers, excipients or diluents, additives such as extenders, binders, disintegrants, pH adjusters, and solubilizers, which are generally used as needed, and then are purified, rescued, encapsulated by commercial formulation techniques. Oral or parenteral medicines such as granules, powders, solutions, emulsions, suspensions, ointments, injections, and skin adhesives, in particular as group II metabolic glutamic acid receptor antagonists.
[91] Although the compound of the present invention can be administered orally or parenterally in an amount of 0.01 to 500 mg once or several times a day for an adult patient, it is preferable to administer orally from the viewpoint of ease of use and efficacy. In addition, the dosage can be appropriately increased or decreased depending on the type of disease to be treated, the age, weight, symptoms, etc. of the patient.
[93] Best Mode for Carrying Out the Invention
[94] Although an Example and a test example are shown to the following and this invention is concretely demonstrated to it, this invention is not limited to these.
[95] Reference Example 1
[96] (1R, 2R, 3R, 5R, 6R) -2-azide-3-hydroxy-6-fluoro-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6- Synthesis of Ethyl Ester
[97] (1) 28.8 mL of a 2.47 M butyllithium hexane solution was added to a 84 mL solution of 7.83 g of tetrahydrofuran cooled to 0 ° C., followed by stirring for 15 minutes. After cooling this solution to -62 ° C, 12.0 g of tetrahydrofuran 40 (1R, 5R, 6R) -6-fluoro-2-oxobicyclo [3.1.0] hexane-6-carboxylic acid ethyl ester The mL solution was added dropwise while maintaining at -62 to -58 ° C. After 1 hour, 25.3 g of tetrahydrofuran 84 mL solution of N-phenyl-bis (trifluoromethanesulfonimide) was added dropwise over 15 minutes while maintaining at -62 to -60 占 폚. The reaction solution was naturally warmed up to room temperature, and further stirred for 1 hour. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with diethyl ether. The organic layer was washed with water and saturated aqueous sodium chloride solution and then dried over anhydrous magnesium sulfate. The drying agent was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200 (manufactured by Wako Pure Chemical Industries, Ltd.), developing solvent: hexane-ethyl acetate = 20: 1). Obtained (1R, 5R, 6R) -6-fluoro-2-trifluoromethanesulfonyloxybicyclo [3.1.0] hexa-2-ene-6-carboxylic acid ethyl ester immediately N, N-dimethyl It was dissolved in 195 mL of formamide, 389 mg of palladium acetate, 910 mg of triphenylphosphine, 12.5 g of benzyl alcohol, and then 11.7 g of triethylamine were added, followed by stirring at room temperature under a carbon monoxide atmosphere for 4.5 hours. 1 N hydrochloric acid was added to the reaction solution, and the mixture was extracted twice with diethyl ether. The organic layers were combined, washed with saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate. The drying agent was filtered off, and the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200 (manufactured by Wako Pure Chemical Industries, Ltd.), developing solvent: hexane-ethyl acetate = 10: 1 to 1: 1). Purification to (1R, 5R, 6R) -6-fluorobicyclo [3.1.0] hexa-2-ene-2,6-dicarboxylic acid 2,6-dicarboxylic acid 2-benzyl ester 6-ethylester 6.42 g were obtained.
[98] mp 90 to 91 ° C
[99] (2) (1R, 5R, 6R) -6-fluorobicyclo [3.1.0] hexa-2-ene-2,6-dicarboxylic acid 2,6 suspended in 150 mL t-butanol and 150 mL water 29.3 g of AD-mix-β (Aldrich) and 5.96 g of methanesulfonamide were added to 6.36 g of -dicarboxylic acid 2-benzyl ester 6-ethyl ester and stirred at 4 ° C for 5 days. Sodium hydrogen sulfite was added to the reaction solution, the mixture was stirred at room temperature for 15 minutes, and then water was added and extracted three times with ethyl acetate. The organic layers were combined, washed with saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. After drying the filtrate, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 10: 1 to 3: 2) (1R, 2S). , 3R, 5R, 6R) 4.21 g of 6-fluoro-2,3-dihydroxybicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester was obtained.
[100]
[101] [α] _D ²⁹ = -45.8 ° (C = 0.202%, chloroform)
[102] (3) (1R, 2S, 3R, 5R, 6R) -6-fluoro-2,3-dihydroxybicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2 cooled to 4 ° C. 1.70 mL of thionyl chloride was added to a 20 mL solution of 3.96 g of dichloromethane of benzyl ester 6-ethyl ester, followed by stirring at 40 ° C. for 13 hours. The solvent and excess reagent were distilled off under reduced pressure and the residue was dissolved in 12 mL of carbon tetrachloride, 12 mL of acetonitrile and 20 mL of water. 3.76 g of sodium metaperiodate and 500 mg of ruthenium trihydrate hydrate were added to the solution, followed by stirring at room temperature for 20 minutes. Water was added to the reaction mixture, followed by extraction three times with diethyl ether. The organic layers were combined, washed with saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. After drying the filtrate, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 5: 1 to 2: 1) (1R, 1aR). , 1bS, 4aR, 5aR) -1-fluoro-3,3-dioxotetrahydro-2,4-dioxa-3λ ⁶ -thiacyclopropa [a] pentalene-1,1b-dicarboxylic acid 4.11 g of 1b-benzyl ester 1-ethyl ester were obtained.
[103]
[104] [α] _D ³⁰ = + 31.3 ° (C = 0.203%, chloroform)
[105] (4) (1R, 1aR, 1bS, 4aR, 5aR) -1-fluoro-3,3-dioxotetrahydro-2,4-di dissolved in 37 mL N, N-dimethylformamide and 3.7 mL water 1.09 g of sodium azide was added to 3.73 g of oxa-3λ ⁶ -thiacyclopropa [a] pentalene-1,1b-dicarboxylic acid 1b-benzylester 1-ethylester and stirred at 50 ° C. for 14 hours. . The solvent was distilled off under reduced pressure, and the residue was dissolved in 187 mL of diethyl ether and 5.2 mL of water, and then 15 mL of 20% sulfuric acid was added thereto, followed by stirring at room temperature for 8 hours. Water was added to the reaction solution, and the mixture was extracted three times with diethyl ether. The organic layers were combined, washed with saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. The drying agent was filtered off, and the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 5: 1 to 1: 1) (1R, 2R). , 3R, 5R, 6R) -2-azide-3-hydroxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester was obtained. .
[106]
[107] [α] _D ³⁰ = -50.2 ° (C = 0.212%, chloroform)
[108] <Example 1>
[109] Synthesis of (1R, 2R, 3R, 5R, 6R) -2-amino-3-methoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
[110] (1) (1R, 2R, 3R, 5R, 6R) -2-azide-3-hydroxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicar dissolved in 0.5 mL of dichloromethane To 500 mg of the acid 2-benzyl ester 6-ethyl ester was added 158 mg of 2,6-di-t-butylpyridine and 113 mg of methyltrifluoromethanesulfonate, followed by stirring at room temperature for 4 days. Poured into 1N hydrochloric acid and extracted three times with diethyl ether. The organic layers were combined, washed with saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. The filtrate was separated by filtration, and the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 9: 1) (1R, 2R, 3R, 5R). , 6R) -2-azide-3-methoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester was obtained.
[111]
[112] MS (ESI) (Pos) m / z: 400 (M + Na) ⁺
[113] (2) (1R, 2R, 3R, 5R, 6R) -2-azide-3-methoxy-6-fluorobicyclo [3.1.0] hexane-2,6 dissolved in 4 mL of acetic acid and 1 mL of water 28 mg of 10% palladium / carbon was added to 280 mg of dicarboxylic acid 2-benzyl ester 6-ethyl ester, followed by stirring at room temperature under a hydrogen atmosphere for 18 hours. The catalyst was filtered off, the filtrate was concentrated under reduced pressure, and the residue was dissolved in 8 mL of 10% hydrochloric acid and heated to reflux for 1.5 hours. After distilling off the solvent under reduced pressure, the residue was purified by ion exchange resin (AG 50W-X8 Resin (type H), developing solvent: water, 50% aqueous tetrahydrofuran solution, 10% pyridine aqueous solution) (1R, 2R, 3R). , 5R, 6R) -2-amino-3-methoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 137 mg were obtained.
[114] <Example 2>
[115] (1R, 2R, 3R, 5R, 6R) -2-amino-3- (4-fluorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl Ester 6-ethylester and (1R, 2R, 3R, 5R, 6R) -2-amino-3- (4-fluorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dica Synthesis of Leric Acid
[116] (1) After washing 79.0 mg of 60% sodium hydride (oil) twice with hexane, it was suspended in 1.9 mL of diethyl ether, and 2.50 g of 4-fluorobenzyl alcohol dissolved in 2.9 mL of diethyl ether was added dropwise. After stirring for 20 minutes at room temperature, 2.70 g of trichloroacetonitrile were added dropwise under cooling with salt-ice. The mixture was further stirred at the temperature for 15 minutes, for 15 minutes under ice-cooling, for 20 minutes under water bath, and for 20 minutes at room temperature. The reaction solution was concentrated under reduced pressure, 1.9 mL of pentane and 75 µl of methanol were added to the residue, followed by vigorous stirring at room temperature for 15 minutes. The inorganic salts were separated by filtration, and the filtrate was concentrated under reduced pressure to obtain 5.28 g of crude 4-fluorobenzyl-2,2,2-trichloroacetimidadate.
[117] 3.40 g of crude 4-fluorobenzyl-2,2,2-trichloroacetimidadate and (1R, 2R, 3R, 5R, 6R) -2-azide-3-hydroxy-6-fluorobicyclo [3.1 3.0 mL of hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester was dissolved in 9.2 mL of dichloromethane and 18.4 mL of cyclohexane. After cooling in an ice bath, 110 [mu] l of trifluoromethanesulfonic acid was added. After stirring at room temperature for 16 hours, the inorganic salt was separated by filtration and saturated aqueous sodium hydrogen carbonate solution was added under ice cooling. After extracting twice with chloroform, the organic layers were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The drying agent was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 10: 1 to 5: 1) (1R, 2R). , 3R, 5R, 6R) -2-azide-3- (4-fluorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6- 1.94 g of ethyl esters were obtained.
[118]
[119] (2) (1R, 2R, 3R, 5R, 6R) -2-azide-3- (4-fluorobenzyloxy) -6-fluorobicyclo [3.1] dissolved in 16 mL tetrahydrofuran and 1.6 mL water. 1.20 mL of 1 M trimethylphosphine / tetrahydrofuran solution was added to 521 mg of .0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester, and stirred for 18 hours at room temperature. After dilution with diethyl ether, the mixture was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, and then dried over anhydrous sodium sulfate. The drying agent was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 2: 1) (1R, 2R, 3R, 5R). 338 mg of 6R) -2-amino-3- (4-fluorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester Got it.
[120] (3) (1R, 2R, 3R, 5R, 6R) -2-amino-3- (4-fluorobenzyloxy) -6-fluorobicyclo [3.1.] Dissolved in 6 mL tetrahydrofuran and 3 mL water. 02.0 hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester 72.0 mg of lithium hydroxide hydrate was added to 304 mg, and the mixture was stirred at room temperature for 31 hours. After distilling off the solvent under reduced pressure, the residue was purified by ion exchange resin (AG 50W-X8 Resin (type H), developing solvent: water, 50% aqueous tetrahydrofuran solution, 10% pyridine aqueous solution) (1R, 2R, 3R). , 5R, 6R) -2-amino-3- (4-fluorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid was obtained.
[121] <Example 3>
[122] (1R, 2R, 3R, 5R, 6R) -2-amino-3-((R ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2 , 6-dicarboxylic acid 2-benzyl ester 6-ethyl ester, to (1R, 2R, 3R, 5R, 6R) -2-amino-3-((S ^* )-1- (naphthalen-2-yl) Methoxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester, (1R, 2R, 3R, 5R, 6R) -2-amino-3- ((R ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid and (1R, 2R, 3R, 5R, 6R Synthesis of) -2-amino-3-((S ^* ) -1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
[123] (1) 23.0 mg of 60% sodium hydride (oily) was washed twice with hexane, suspended in 0.8 mL of tetrahydrofuran, and 1.00 g of 1- (naphthalen-2-yl) ethanol dissolved in 1.2 mL of tetrahydrofuran. Was added dropwise. After stirring for 20 minutes at room temperature, 0.58 mL of trichloroacetonitrile was added dropwise under cooling with salt-ice. The mixture was further stirred for 20 minutes at the above temperature, 20 minutes under ice cooling, 30 minutes under water bath, and 50 minutes at room temperature. The reaction solution was concentrated under reduced pressure, 5 mL of pentane, 19 μl of methanol and 0.5 mL of tetrahydrofuran were added to the residue, followed by vigorous stirring at room temperature for 10 minutes. The inorganic salts were separated by filtration, and the filtrate was concentrated under reduced pressure to obtain 1.84 g of crude 1- (naphthalen-2-yl) ethyl-2,2,2-trichloroacetimidadate.
[124] 590 mg of crude 1- (naphthalen-2-yl) ethyl-2,2,2-trichloroacetimidadate and (1R, 2R, 3R, 5R, 6R) -2-azide-3-hydroxy-6- 450 mg of fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester were dissolved in 1.5 mL of dichloromethane and 3.0 mL of cyclohexane, and 17 [mu] l of trifluoromethanesulfonic acid was added. Added. After stirring for 1 hour at room temperature, the inorganic salts were separated by filtration and saturated aqueous sodium hydrogen carbonate solution was added under ice cooling. After extracting twice with chloroform, the organic layers were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. After filtering off the desiccant, the filtrate was concentrated under reduced pressure, and the residue was subjected to column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 13: 1 to 5: l) and (silica gel: MS GEL) Purified by SIL D-75-60 A (manufactured by Toka Chemical Industries, Ltd.), developing solvent: hexane-ethyl acetate = 13: 1) (1R, 2R, 3R, 5R, 6R) -2-azide-3 -((R ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester (Rf Value: 0.55, developing solvent: hexane-ethyl acetate = 3: 1, TLC: silica gel 60F ₂₅₄ ) 271 mg and (1R, 2R, 3R, 5R, 6R) -2-azide-3-((S ^* ) -1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester (Rf value: 0.49, developing solvent) : Hexane-ethyl acetate = 3: 1, TLC: silica gel 60F ₂₅₄ ) 301 mg were obtained.
[125] (1R, 2R, 3R, 5R, 6R) -2-azide-3-((R ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane- 2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester:
[126]
[127] (1R, 2R, 3R, 5R, 6R) -2-azide-3-((S ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane- 2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester:
[128]
[129] (2) (1R, 2R, 3R, 5R, 6R) -2-azide-3-((R ^* )-1- (naphthalen-2-yl) ethoxy in the same manner as in (2) of Example 2 266 mg) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester and (1R, 2R, 3R, 5R, 6R) -2-azide- 3-((S ^* ) -1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester 238 From mg (1R, 2R, 3R, 5R, 6R) -2-amino-3-((R ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane 164 mg of -2,6-dicarboxylic acid 2-benzyl ester 6-ethylester and (1R, 2R, 3R, 5R, 6R) -2-amino-3-((S ^* ) -1- (naphthalene-2 153 mg of -yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester were obtained, respectively.
[130] (3) (1R, 2R, 3R, 5R, 6R) -2-amino-3-((R ^* )-1- (naphthalen-2-yl) ethoxy) in the same manner as in Example 2 (3) 158 mg of -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzylester 6-ethylester and (1R, 2R, 3R, 5R, 6R) -2-amino-3- ((S ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester from 148 mg (1R, 2R, 3R, 5R, 6R) -2-amino-3-((R ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluorobicyclo [3.1.0] hexane-2 96.0 mg, 6-dicarboxylic acid and (1R, 2R, 3R, 5R, 6R) -2-amino-3-((S ^* )-1- (naphthalen-2-yl) ethoxy) -6-fluoro 72.0 mg of lobbycyclo [3.1.0] hexane-2,6-dicarboxylic acid were obtained.
[131] <Example 4>
[132] Synthesis of (1R, 2R, 3R, 5R, 6R) -2-amino-3-propyloxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
[133] (1) (1R, 2R, 3R, 5R, 6R) -2-amino-3- (2-propenyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6 dissolved in 1 mL of water -40 mg of dicarboxylic acid was added 4 mg of 10% palladium / carbon, followed by stirring for 2 days at room temperature under hydrogen atmosphere. The catalyst was filtered off, the filtrate was concentrated under reduced pressure, and then 1 mL of tetrahydrofuran was added and the mixture was heated to reflux for 1 hour. After stirring for 3 hours at room temperature, the solids were separated by filtration, purified by ion exchange resin (AG 50W-X8 Resin (H type), developing solvent: water, 50% tetrahydrofuran aqueous solution, 10% pyridine aqueous solution) 30 mg of (1R, 2R, 3R, 5R, 6R) -2-amino-3-propyloxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid were obtained.
[134] Example 5
[135] Synthesis of (1R, 2R, 3R, 5R, 6R) -2-amino-3-cyclopentyloxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
[136] (1) 375 mg of crude 2-cyclopentenyl-2,2,2-trichloroacetimidadate obtained from 2-cyclopenten-1-ol in the same manner as in (1) of Example 2 and (1R, 2R, 3R, 5R, 6R) -2-azide-3-hydroxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethylester from 650 mg (1R , 2R, 3R, 5R, 6R) -2-azide-3- (2-cyclopentenyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2-benzyl ester 339 mg of 6-ethylester were obtained.
[137]
[138] (2) (1R, 2R, 3R, 5R, 6R) -2-azide-3- (2-cyclopentenyloxy) -6-fluorobicyclo [3.1.0] dissolved in 18 mL of acetic acid and 6 mL of water. ] To 331 mg of hexane-2,6-dicarboxylic acid 2-benzyl ester 6-ethyl ester was added 39 mg of 10% palladium / carbon, followed by stirring at room temperature under hydrogen atmosphere for 24 hours. The catalyst was separated by filtration, the filtrate was concentrated under reduced pressure, the residue was dissolved in 7.36 mL of tetrahydrofuran and 3.53 mL of water, and 80 mg of lithium hydroxide hydrate was added thereto, followed by stirring at room temperature for 4 hours. After distilling off the solvent under reduced pressure, the residue was purified by ion exchange resin (AG 50W-X8 Resin (type H), developing solvent: water, 50% aqueous tetrahydrofuran solution, 10% pyridine aqueous solution) (1R, 2R, 3R). , 5R, 6R) -2-amino-3-cyclopentyloxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid was obtained 61 mg.
[139] <Example 6>
[140] (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3-nitrobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester, (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3-aminobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester and Synthesis of (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3-aminobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid
[141] (1) 562 mg of crude 3-nitrobenzyl-2.2,2-trichloroacetimidadate obtained from 3-nitrobenzyl alcohol in the same manner as in (1) of Example 2 and (1R, 2R, 3R, 5R, 6R) From 380 mg of 2-azide-3-hydroxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester (1R, 2R, 3R, 5R, 6R) -2 279 mg of -azide-3- (3-nitrobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester were obtained.
[142]
[143] (2) (1R, 2R, 3R, 5R, 6R) -2-azide-3- (3-nitrobenzyloxy) -6-fluorobicyclo [3.1.0] similarly to (2) of Example 2 From 275 mg of hexane-2,6-dicarboxylic acid diethyl ester (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3-nitrobenzyloxy) -6-fluorobicyclo [3.1. 0] hexane-2,6-dicarboxylic acid diethyl ester 120 mg was obtained.
[144] (3) (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3-nitrobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6 dissolved in 0.21 mL of acetic acid 101 mg of zinc powder was added to 120 mg of dicarboxylic acid diethyl ester, followed by stirring at room temperature for 3 hours. The solid was filtered off and ice-cold saturated sodium hydrogen carbonate was added. After extraction twice with ethyl acetate, the organic layers were combined, washed with 0.5 M aqueous sodium carbonate solution and saturated brine, and dried over anhydrous sodium sulfate. The drying agent was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: chloroform-ethanol = 30: 1) to obtain (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3-aminobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester was obtained.
[145] (4) (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3-aminobenzyloxy) -6-fluorobicyclo [3.1.0] hexane similarly to (3) of Example 2 From 90 mg of -2,6-dicarboxylic acid diethyl ester (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3-aminobenzyloxy) -6-fluorobicyclo [3.1.0 ] 60 mg of hexane-2,6-dicarboxylic acid was obtained.
[146] <Example 7>
[147] Of (1R, 2R, 3S, 5R, 6R) -2-azide-3-hydroxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2,6-diethylester synthesis
[148] (1) (1R, 2R, 3R, 5R, 6R) -2-azide-3-hydroxy-6-fluoro-bicyclo [3.1.0] hexane-2 dissolved in 20 mL of dichloromethane under nitrogen atmosphere 78 µl of trifluoromethanesulfonic anhydride dissolved in 0.4 mL of dichloromethane at -75 ° C was added dropwise to 120 mg of 6-dicarboxylic acid 2,6-diethyl ester, followed by stirring for 1.5 hours under ice-cooling. 48 μl of pyridine and 39 μl of trifluoromethanesulfonic anhydride dissolved in 0.2 mL of dichloromethane were added dropwise at −75 ° C., followed by stirring for 25 minutes under ice-cooling. After addition of 10 mL of ether, the solid was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel Waco gel C200, developing solvent: hexane-ethyl acetate = 5: 1) (1R, 2R, 3R, 5R, 6R) -2-azide-3-trifluoromethanesulfonyloxy-6-fluoro-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2,6- 166 mg of diethyl ester were obtained.
[149]
[150] [α] _D ²⁶ = -31.2 ° (C = 0.43%, Chloroform)
[151] (2) (1R, 2R, 3R, 5R, 6R) -2-azide-3-trifluoromethanesulfonyloxy-6-fluoro-bicyclo [1] dissolved in 6.9 mL of N, N-dimethylformamide. 3.1.0] 688 mg of potassium nitrite and 428 mg of 18-crown-6 were added to 701 mg of hexane-2,6-dicarboxylic acid 2,6-diethyl ester, followed by stirring at room temperature under nitrogen atmosphere for 1.5 days. After that, the mixture was further stirred at 45 ° C for 3.5 days. After adding water, the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The drying agent was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 5: 1) (1R, 2R, 3S, 5R, 388 mg of 6R) -2-azide-3-hydroxy-6-fluoro-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2,6-diethylester was obtained.
[152]
[153] [α] _D ²⁵ = + 6.4 ° (C = 0.96%, Chloroform)
[154] <Example 8>
[155] (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 2, 6-diethyl ester and (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6- Synthesis of dicarboxylic acid 2-ethyl ester
[156] (1) 3.17 g of crude 3,4-dichlorobenzyl-2,2,2-trichloroacetimidadate obtained from 3,4-dichlorobenzyl alcohol similarly to (1) of Example 2 and (1R, 2R, From 1.98 g of 3R, 5R, 6R) -2-azide-3-hydroxy-6-fluoro-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethylester (1R, 2R, 3R, 5R, 6R) -2-azide-3- (3,4-dichlorobenzyloxy) -6-fluoro-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester 1.16 g was obtained.
[157]
[158] [α] _D ²⁸ = -12.6 ° (C = 1.14%, chloroform)
[159] (2) (1R, 2R, 3R, 5R, 6R) -2-azide-3- (3,4-dichlorobenzyloxy) -6-fluoro-bicyclo [2] 3.1.0] from 1.11 g of hexane-2,6-dicarboxylic acid diethyl ester (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6- 878 mg of fluoro-bicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester was obtained.
[160] (3) (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1 dissolved in 3.5 mL of tetrahydrofuran and 1.7 mL of water. 17.8 mg of lithium hydroxide hydrate was added to 150 mg of .0] hexane-2,6-carboxylic acid 2-ethyl ester, and the mixture was stirred for 2 hours under ice cooling. After adding 0.45 mL of 1 N hydrochloric acid, the total amount was diluted to 50 mL with water, and an ion exchange resin (AG 50W-X8 Resin (type H), developing solvent: water, 50% tetrahydrofuran aqueous solution, 10% pyridine aqueous solution) Purification with (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-carboxylic acid 107 mg of 2-ethyl ester were obtained.
[161] Example 9
[162] (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-carboxylic acid 6-ethyl Synthesis of Ester Hydrochloride
[163] (1) (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluoro-bicyclo [3.1 like (3) of Example 2 .0] from 304 mg of hexane-2,6-dicarboxylic acid diethyl ester (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluoro 195 mg of ubicyclo [3.1.0] hexane-2,6-dicarboxylic acid were obtained.
[164] (2) (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2 dissolved in 1.1 mL of ethanol After adding 88 µl of 6-dicarboxylic acid and 88 µl of thionyl chloride at room temperature under a nitrogen atmosphere, the mixture was stirred at 50 ° C for 1 hour, the solids were collected by filtration, and the filtrate was concentrated under reduced pressure. 1.38 mL of propylether was added and stirred for 17 hours at room temperature to filter off the solid. The solid was washed with isopropyl ether to give (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2, 114 mg of 6-dicarboxylic acid 6-ethylester hydrochloride were obtained.
[165] <Example 10>
[166] (1R, 2R, 3R, 5R, 6R) -2-[(2'S)-(2'-aminopropionyl) amino] -3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1. 0] Synthesis of hexane-2,6-dicarboxylic acid hydrochloride
[167] (1) To 316 mg of Nt-butoxycarbonyl-L-alanine dissolved in 6.9 mL of dichloromethane, 184 μl of N-methylmorpholine and 218 μl of isobutyl chloroformate were added at -14 ° C. under a nitrogen atmosphere, followed by stirring for 1 minute. Then (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluoro-bicyclo [3.1.0] dissolved in 6.9 mL of dichloromethane. After dropping 691 mg of hexane-2,6-dicarboxylic acid diethyl ester, the mixture was stirred at room temperature for 30 minutes. The reaction solution was washed twice with 1 N hydrochloric acid and dried over anhydrous sodium sulfate. The drying agent was filtered off, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 2: 1) (1R, 2R, 3R, 5R). , 6R) -2-[(2'S)-(2'-t-butoxycarbonylaminopropionyl) amino] -3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] 902 mg of hexane-2,6-dicarboxylic acid diethyl ester were obtained.
[168]
[169] [α] _D ²⁴ = -33.6 ° (C = 0.42%, Chloroform)
[170] (2) (1R, 2R, 3R, 5R, 6R) -2-[(2'S)-(2'-t-butoxycarbonylaminopropionyl) amino] -3- (dissolved in 6 mL of tetrahydrofuran) To 45.5 mg of 3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester, add 6 mL of 2.5 M aqueous lithium hydroxide solution and stir at room temperature for 2 days. It was. The reaction solution was extracted three times with ethyl acetate, and the organic layers were combined and dried over anhydrous sodium sulfate. The drying agent was filtered off and the filtrate was concentrated under reduced pressure to give crude (1R, 2R, 3R, 5R, 6R) -2-[(2'S)-(2'-t-butoxycarbonylaminopropionyl) amino]- 470 mg of 3- (3,4-chlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 6-lithium-2-ethylester were obtained.
[171] Crude (1R, 2R, 3R, 5R, 6R) -2-[(2'S)-(2'-t-butyloxyaminopropionyl) amino] -3- (3,4-chlorobenzyl dissolved in 7.5 mL of water To 375 mg of oxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid 6-lithium 2-ethyl ester, 135 mg of lithium hydroxide hydrate was added at room temperature, followed by 8 at 45 ° C. Stir for days. The reaction solution was washed 10 times with ethyl acetate, adjusted to pH 2 with 1 N hydrochloric acid under ice-cooling, and the aqueous solution was extracted three times with ethyl acetate. The combined organic layers were washed with saturated brine and dried over anhydrous sodium sulfate. After the drying agent was filtered off, the filtrate was concentrated under reduced pressure.
[172] 4.6 mL of 4M hydrogen chloride / ethyl acetate solution was added to the residue under ice-cooling, and the mixture was stirred at room temperature for 15 hours. The precipitated solid was separated by filtration, and the solid was washed with ethyl acetate (1R, 2R, 3R, 5R, 6R) -2-[(2'S)-(2'-aminopropionyl) amino] -3- (3, 138 mg of 4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid hydrochloride were obtained.
[173] <Example 11>
[174] (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-[(1'S)-(1'-hydroxycarbonyl-3'-methylbutylcarb Barmoyl)]-6-fluorobicyclo [3.1.0] hexane-2-carboxylic acid
[175] (1) (1R, 2R, 3R, 5R, 6R) -2-azide-3- (3,4-dichlorobenzyloxy) -6-fluoro-ratio dissolved in 8.5 mL of N, N-dimethylformamide To 854 mg of cyclo [3.1.0] hexane-2,6-dicarboxylic acid diethyl ester and 464 mg of leucine ethyl ester hydrochloride, 261 μl of N-methylmorpholine was added at room temperature, followed by 1-hydroxy under ice-cooling. 378 mg of benzotriazole and 464 mg of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide were added and stirred at room temperature for 12 hours. Ethyl acetate was added to the reaction solution, which was then washed with 1N hydrochloric acid and saturated brine, and dried over anhydrous sodium sulfate. After the drying agent was filtered off, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel: Waco gel C200, developing solvent: hexane-ethyl acetate = 8: 1) to give (1R, 2R, 3R, 5R, 6R) -2-azide-3- (3, 4-dichlorobenzyloxy) -6-[(1'S)-(1'-ethoxycarbonyl-3'-methylbutylcarbamoyl)]-6-fluorobicyclo [3.1.0] hexane-2-carboxyl 998 mg of acid ethyl ester were obtained.
[176]
[177] [α] _D ²⁸ = -20.0 ° (C = 0.39%, Chloroform)
[178] (2) As in (2) of Example 2, (1R, 2R, 3R, 5R, 6R) -2-azide-3- (3,4-dichlorobenzyloxy) -6-[(1'S)- (1'-ethoxycarbonyl-3'-methylbutylcarbamoyl)]-6-fluorobicyclo [3.1.0] hexane-2-carboxylic acid ethyl ester from 996 mg (1R, 2R, 3R, 5R , 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-[(1'S)-(1'-ethoxycarbonyl-3'-methylbutylcarbamoyl)]-6-fluoro Robicyclo [3.1.0] hexane-2-carboxylic acid ethyl ester
[179]
[180] [α] _D ²² = + 2.4 ° (C = 0.65%, Chloroform)
[181] (3) As in (3) of Example 2, (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-[(1'S)-( 1'-ethoxycarbonyl-3'-methylbutylcarbamoyl)]-6-fluorobicyclo [3.1.0] hexane-2-carboxylic acid ethyl ester from 400 mg (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-[(1'S)-(1'-hydroxycarbonyl-3'-methylbutylcarbamoyl)]-6-fluorobi 250 mg of cyclo [3.1.0] hexane-2-carboxylic acid were obtained.
[182] Hereinafter, the structure and the physical property data of the compound of Example 1, 2, 3, 4, 5, 6, 8, 9, 10, and 11 and the compound obtained in the same way are shown in following Table 1.
[183]
[184]
[185]
[186]
[187]
[188]
[189]
[190]
[191]
[192]
[193]
[194]
[195]
[196]
[197]
[198]
[199]
[200]
[201]
[202]
[203]
[204]
[205]
[206]
[207]
[208]
[209]
[210]
[211]
[212]
[213]
[214]
[215]
[216]
[217] <Test Example 1>
[218] (Effects on cAMP accumulation in metabolic glutamic acid receptor mGluR2 stable expressing CHO cells of test subjects (antagonism))
[219] Metabolic glutamic acid receptor mGluR2 stable expressing CHO cells, Dulbecco's modified Eagle's medium containing 10% dialysis fetal bovine serum [1% proline, 50 units / ml penicillin, 50 μg / ml streptomycin, 2 mM L-glutamine (added before use) ) to the, 1.26 × 10 ⁴ cells / well were subjected to culture for 2 days under /0.32 cm ² / at a rate of 150 ㎕ seeded in a 96-well plate, and 37 ℃, 5% CO ₂ used. Subsequently, exchange with 1-glutamine free medium, and after 4 hours, the supernatant was aspirated to remove 150 μl of PBS (+)-IBMX (10 mM PBS (−), 1 mM MgCl ₂ , 1 mM CaCl ₂ , 1). mM IBMX) was added and incubated for 20 minutes in the presence of 37 ° C., 5% CO ₂ . Again, the supernatant was aspirated off and PBS (+)-IBMX containing 60 μl of 10 ⁻⁵ M forskolin, 30 μM glutamic acid, and 10 ⁻¹⁰ to 10 ⁻⁴ M of the test was added for 15 minutes at 37 ° C. Incubation was carried out in the presence of 5% CO ₂ , and the antagonistic effect of the test on glutathic acid-inhibited inhibition of forskolin-stimulated cAMP accumulation was examined (control under conditions of no compound addition (Tanabe et al, Neuron, 8, 169- 179 (1992)) 100 μl of ice-cold ethanol was added to stop the reaction, and the total amount of the supernatant was collected on a separate plate, and then dried at room temperature in an evaporator and stored at -20 ° C. The dried samples were cAMP EIA kit. The amount of cAMP was quantified using (Amarsham Co., Ltd.) The control value was subtracted from each cAMP amount Test subject antagonizing the inhibition of 30 μM glutamic acid by 50% against cAMP increase by 10 ⁻⁵ M forskolin stimulation The concentration was determined as the IC ₅₀ value.
[220] In the general formula (I) of the compound of the present invention, a compound in which R ¹ and R ² are hydroxy and R ³ is represented by a hydrogen atom, that is, compounds 1 to 58 in Table 1, has an IC ₅₀ value of 500 in the measurement described in this test example. Strong antagonism of less than nM was shown. For example, compounds 1, 6, 22, 28, 34, 42 and 52 exhibited IC ₅₀ values of 229 nM, 131 nM, 29.1 nM, 40.8 nM, 20.0 nM, 22.7 nM and 24.4 nM, respectively.
[221] <Test Example 2>
[222] (Effect on [ ³ H] MGS0008 Receptor Binding Test in Metabolic Glutamic Acid Receptor mGluR2 Stable Expressed CHO Cells of Test Subjects
[223] Metabolic glutamic acid receptor mGluR2 stable expressing CHO cells, Dulbecco's modified Eagle's medium containing 10% dialysis fetal bovine serum [1% proline, 50 units / ml penicillin, 50 μg / ml streptomycin, 2 mM L-glutamine (added before use) )] Was seeded into a T-225 flask, and cultured at 37 ° C and 5% CO ₂ . The cells were washed with PBS (-) twice in a confluent state, and the cells were peeled off with a scraper, and the cells were recovered by centrifugation at 4 ° C for 1000 x g for 15 minutes. The precipitate obtained was stored at -80 ° C. It was dissolved before use and suspended in 50 mM Tris-HCl buffer (pH 7.4). The suspension was homogenized for 20 seconds with a homogenizer, and then centrifuged at 4 DEG C for 48,000 x g for 20 minutes to obtain a precipitate. After resuspending and homogenizing with the said buffer solution, it incubated at 37 degreeC for 15 minutes, and centrifuged at 4 degreeC, 48,000xg, and 20 minutes. The precipitate obtained was further centrifuged twice and then homogenized with 50 mM Tris-HCl buffer (2 mM MgCl, pH 7.4) to obtain a membrane fraction. Receptor binding tests were performed in the range of membrane concentration of 50-200 μg / 0.5 ml assay. The test agent was added to the membrane fraction and 3 nM [ ³ H] MGSO008 was added and incubated at 25 ° C for 1 hour. The reaction was stopped by suction filtration on a Whatman GF / C filter previously immersed in 0.3% polyethyleneimine using a Brandel cell harvester. After suction filtration, the filter was washed three times with 3 ml of ice cold 50 mM Tris-HCl buffer (2 mM MgCl ₂ , pH 7.4). 10 ml of Aquasol-2 was added to the obtained filter and left for 6 hours or longer, and fluorescence activity was measured with a Beckman LS6000 liquid scintillation counter. Nonspecific binding was measured in the presence of 10 μM LY354740 and subtracted from each binding amount. The concentration IC ₅₀ value of the test agent inhibited by 50% with respect to the [ ³ H] MGSO008 binding amount by the solvent was determined.
[224] In the general formula (I) of the compound of the present invention, a compound in which R ¹ and R ² are hydroxy and R ³ is represented by a hydrogen atom, that is, compounds 1 to 58 in Table 1, is selected from the _A value of ₅₀ showed a strong binding action of 100 nM or less.
[225] <Test Example 3>
[226] (Evaluation of antidepressant action by rat forced swimming test)
[227] (1) Female SD rats (weight 220 to 240 g, Nippon Charles River Japan) were used as experimental animals.
[228] (2) The following compound was used as a test drug.
[229] LY341495 (Journal of Medicinal Chemistry 1998, 41, 358-378): (2S) -2-amino-2-((1S, 2S) -2-carboxycycloprop-1-yl) -3- (9-k Xanthyl) propionic acid
[230] ((2S) -2-Amino-2-((1S, 2S) -2-carboxycycloprop-1-yl) -3- (9-xanthyl) propanoic acid)
[231] Compound 34: (1R, 2R, 3R, 5R, 6R) -2-amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxyl mountain
[232] ((1S, 2R, 3R, 5R, 6R) -2-Amino-3- (3,4-dichlorobenzyloxy) -6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid)
[233] (3) The forced swimming test was conducted with a slight modification to the method reported by Porsolt et al. (European Journal of Pharmacology 1978, 47, 379-391). That is, the rats were placed in a 30 cm deep cylinder containing water, first subjected to 15 minutes of forced swimming, and after 24 hours, a 5-minute forced swimming test (this test) was conducted. In addition, the immobility time in this test was measured to evaluate the antidepressant action of the test drug.
[234] In addition, in the administration group, each test drug of LY341495 and Compound 34 was dissolved in 1/15 M phosphate buffer, and at the rate of 0.3 mg / kg, 1 mg / kg, 3 mg / kg, 24 hours before and 1 of this test. Administration was intraperitoneally twice before time. In addition, only 1/15 M of phosphate buffer was administered intraperitoneally to the solvent group.
[235] (4) Symbols * and ** in FIGS. 1 and 2 are solvent groups that are 1/15 M phosphate buffers with P <0.05 and P <0.01, respectively, when significant differences were tested by Dunnett's test. This indicates that there is an edge difference compared to the above. Therefore, it was found from FIGS. 1 and 2 that the group intraperitoneally administered the test drug LY341495 and compound 34 compared to the solvent group had a significant dose-dependent decrease in immobility time, thereby exhibiting an excellent antidepressant effect. This indicates that compounds having group II metabolic glutamic acid receptor antagonism are useful as antidepressants.
[236] With the present invention, metabolic glutamic acid receptor antagonists have been found to be effective against depressive symptoms, making it possible to provide new types of antidepressants.
[237] Further, 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative, one of the embodiments of the present invention, a pharmaceutically acceptable salt thereof or a hydrate thereof, It is a potent antagonist of metabolic glutamic acid receptors. Therefore, treatment and prevention of psychological disorders such as ataxia (anxiety disorder), anxiety and related diseases, bipolar disorder, epilepsy, and drug dependence, cognitive impairment, Alzheimer's disease, Huntington's chorea, Parkinson's disease, and muscular rigidity It is also possible to provide medicines for the treatment and prevention of neurological diseases such as exercise disorders, cerebral ischemia, brain failure, spinal cord disorders, and head disorders.

权利要求:
Claims (30)
[1" claim-type="Currently amended] An antidepressant comprising as an active ingredient a compound having group II metabotropic glutamic acid receptor antagonism.
[2" claim-type="Currently amended] 2-Amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative represented by the following formula (I), a pharmaceutically acceptable salt thereof or a hydrate thereof.
<Formula I>

Wherein R ¹ and R ² are the same or different and are a C _1-6 alkoxy group substituted with hydroxy, a C _1-10 alkoxy group, a phenoxy group, a naphthyloxy group, one or two phenyl groups, C _{1 -6} alkoxyC _1-6 alkoxy group, hydroxyC _2-6 alkoxy group, amino group, amino group substituted by one or two C _1-6 alkyl groups same or different, one or two identical or different Amino group substituted by C _1-6 alkoxyC _1-6 alkyl group, amino group substituted by one or two hydroxyC _2-6 alkyl groups, identical or different, one or two C _1- same or different Amino group substituted by ₆ alkoxycarbonylC _1-6 alkyl group, or NR ⁶ -CHR ⁷ -A-CO ₂ R ⁸ , wherein R ⁶ and R ⁷ are the same or different and are a hydrogen atom, hydroxy C _1-6 alkyl group, a hydroxy-carbonyl C _1-6 alkyl group, a C _1-10 alkyl group, a phenyl group, a phenyl C _1-6 alkyl group, a hydroxy Fe Group, a hydroxyphenyl-C _1-6 alkyl group, a naphthyl group, a naphthyl C _1-6 alkyl group, an aromatic heterocyclic C _1-6 alkyl, C _1-6 alkoxy C _1-6 alkyl, amino C _2-6 alkyl group, a sphere Or anininoC _2-6 alkyl group, mercaptoC _2-6 alkyl group, C _1-6 alkylthioC _1-6 alkyl group, aminocarbonylC _1-6 alkyl group, or R ⁶ and R ⁷ It may represent a group which forms a methylene group, an ethylene group, or a propylene group, may mutually combine, and may form a cyclic amino group, R <^8> represents a protecting group of a hydrogen atom or a carboxyl group, A represents a single bond, a methylene group, an ethylene group, or a propylene group Represents a natural or non-natural amino acid residue represented by
R ³ is C _1-10 acyl group, C _1-6 alkoxyC _1-6 acyl group, hydroxyC _2-10 acyl group, C _1-6 alkoxycarbonylC _1-6 acyl group, hydroxycarbonyl C An amino acid residue represented by _1-6 acyl group or R ⁹ -NH-A-CHR ⁷ -CO (wherein R ⁷ and A have the same meaning as described above and R ⁹ represents a protecting group of a hydrogen atom or an amino group) Indicate,
R ⁴ and R ⁵ are the same or different and a 5-membered heteroaromatic ring containing one or more hydrogen atoms, a C _1-10 alkyl group, a C _2-10 alkenyl group, a phenyl group, a naphthyl group, a hetero atom, or a halogen atom Substituted with 1 to 5 substituents selected from the group consisting of C _1-10 alkyl, C _1-10 alkoxy, trifluoromethyl, phenyl, hydroxycarbonyl, amino, nitro, cyano and phenoxy groups It may represent a phenyl group, or R ⁴ and R ⁵ may be bonded to each other to form a cyclic structure.
[3" claim-type="Currently amended] The 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6 according to claim 2, wherein in formula (I), R ¹ and R ² are hydroxy and R ³ is a hydrogen atom. -Dicarboxylic acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[4" claim-type="Currently amended] ^3. 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicar according to claim 2, wherein in formula (I), R ¹ is hydroxy and R ³ is a hydrogen atom. Acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[5" claim-type="Currently amended] ^3. 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicar according to claim 2, wherein in formula (I), R ² is hydroxy and R ³ is a hydrogen atom. Acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[6" claim-type="Currently amended] The 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in formula (I), R ¹ and R ² are hydroxy. Pharmaceutically acceptable salts or hydrates thereof.
[7" claim-type="Currently amended] 2-Amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative represented by the following formula (II), a pharmaceutically acceptable salt thereof or a hydrate thereof.
<Formula II>

Wherein R ¹ and R ² are the same or different and are a C _1-6 alkoxy group substituted with hydroxy, a C _1-10 alkoxy group, a phenoxy group, a naphthyloxy group, one or two phenyl groups, C _{1 -6} alkoxyC _1-6 alkoxy group, hydroxyC _2-6 alkoxy group, amino group, amino group substituted by one or two C _1-6 alkyl groups same or different, one or two identical or different Amino group substituted by C _1-6 alkoxyC _1-6 alkyl group, amino group substituted by one or two hydroxyC _2-6 alkyl groups, identical or different, one or two C _1- same or different Amino group substituted by ₆ alkoxycarbonylC _1-6 alkyl group, or NR ⁶ -CHR ⁷ -A-CO ₂ R ⁸ , wherein R ⁶ and R ⁷ are the same or different and are a hydrogen atom, hydroxy C _1-6 alkyl group, a hydroxy-carbonyl C _1-6 alkyl group, a C _1-10 alkyl group, a phenyl group, a phenyl C _1-6 alkyl group, a hydroxy Fe Group, a hydroxyphenyl-C _1-6 alkyl group, a naphthyl group, a naphthyl C _1-6 alkyl group, an aromatic heterocyclic C _1-6 alkyl, C _1-6 alkoxy C _1-6 alkyl, amino C _2-6 alkyl group, a sphere Or anininoC _2-6 alkyl group, mercaptoC _2-6 alkyl group, C _1-6 alkylthioC _1-6 alkyl group, aminocarbonylC _1-6 alkyl group, or R ⁶ and R ⁷ It may represent a group which forms a methylene group, an ethylene group, or a propylene group, may mutually combine, and may form a cyclic amino group, R <^8> represents a protecting group of a hydrogen atom or a carboxyl group, A represents a single bond, a methylene group, an ethylene group, or a propylene group Represents a natural or non-natural amino acid residue represented by
R ³ is C _1-10 acyl group, C _1-6 alkoxyC _1-6 acyl group, hydroxyC _2-10 acyl group, C _1-6 alkoxycarbonylC _1-6 acyl group, hydroxycarbonyl C Amino acid residue represented by _1-6 acyl group or R ⁹ -NH-A-CHR ⁷ -CO, wherein R ⁷ and A have the same meaning as described above, and R ⁹ represents a hydrogen atom or a protecting group of an amino group. Indicate,
R ⁴ and R ⁵ are the same or different and a 5-membered heteroaromatic ring containing one or more hydrogen atoms, a C _1-10 alkyl group, a C _2-10 alkenyl group, a phenyl group, a naphthyl group, a hetero atom, or a halogen atom Substituted with 1 to 5 substituents selected from the group consisting of C _1-10 alkyl, C _1-10 alkoxy, trifluoromethyl, phenyl, hydroxycarbonyl, amino, nitro, cyano and phenoxy groups It may represent a phenyl group, or R ⁴ and R ⁵ may be bonded to each other to form a cyclic structure.
[8" claim-type="Currently amended] The 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6 according to claim 7, wherein in formula (II), R ¹ and R ² are hydroxy and R ³ is a hydrogen atom. -Dicarboxylic acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[9" claim-type="Currently amended] 8. 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicar according to claim 7, wherein in formula (II), R ¹ is hydroxy and R ³ is a hydrogen atom. Acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[10" claim-type="Currently amended] The method of claim 7 wherein, in the formula II, R ¹ is hydroxy, and R ³ is a hydrogen atom, R ² is C _1-10 alkoxy group or a C _1-6 alkoxy group substituted with one phenyl group of 2-amino 3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2.6-dicarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof.
[11" claim-type="Currently amended] 8. A 2-amino-3-alkoxy-6-fluorobicyclo according to claim 7, wherein in formula II, R ¹ is hydroxy, R ³ is a hydrogen atom, and R ² is NH-CHR ⁷ -CO ₂ H. [3.1.0] hexane-2,6-dicarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof.
[12" claim-type="Currently amended] 8. 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicar according to claim 7, wherein in formula (II), R ² is hydroxy and R ³ is a hydrogen atom. Acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[13" claim-type="Currently amended] The ² -amino according to claim 7, wherein in formula (II), R ² is hydroxy, R ³ is a hydrogen atom, and R ¹ is a C _1-6 alkoxy group substituted with a C _1-10 alkoxy group or one phenyl group. 3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof.
[14" claim-type="Currently amended] 8. A 2-amino-3-alkoxy-6-fluorobicyclo according to claim 7, wherein in formula (II), R ² is hydroxy, R ³ is a hydrogen atom, and R ¹ is NH-CHR ⁷ -CO ₂ H. [3.1.0] hexane-2,6-dicarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof.
[15" claim-type="Currently amended] The 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein R ¹ and R ² in formula II are hydroxy, Pharmaceutically acceptable salts or hydrates thereof.
[16" claim-type="Currently amended] 8. A 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0 according to claim 7 wherein R ¹ and R ² in formula II are hydroxy and R ³ is H ₂ N—CHR ⁷ —CO. ] Hexane-2,6-dicarboxylic acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[17" claim-type="Currently amended] 2-Amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative represented by the following formula (III), a pharmaceutically acceptable salt thereof or a hydrate thereof.
<Formula III>

Wherein R ¹ and R ² are the same or different and are a C _1-6 alkoxy group substituted with hydroxy, a C _1-10 alkoxy group, a phenoxy group, a naphthyloxy group, one or two phenyl groups, C _{1 -6} alkoxyC _1-6 alkoxy group, hydroxyC _2-6 alkoxy group, amino group, amino group substituted by one or two C _1-6 alkyl groups same or different, one or two identical or different Amino group substituted by C _1-6 alkoxyC _1-6 alkyl group, amino group substituted by one or two hydroxyC _2-6 alkyl groups, identical or different, one or two C _1- same or different Amino group substituted by ₆ alkoxycarbonylC _1-6 alkyl group, or NR ⁶ -CHR ⁷ -A-CO ₂ R ⁸ , wherein R ⁶ and R ⁷ are the same or different and are a hydrogen atom, hydroxy C _1-6 alkyl group, a hydroxy-carbonyl C _1-6 alkyl group, a C _1-10 alkyl group, a phenyl group, a phenyl C _1-6 alkyl group, a hydroxy Fe Group, a hydroxyphenyl-C _1-6 alkyl group, a naphthyl group, a naphthyl C _1-6 alkyl group, an aromatic heterocyclic C _1-6 alkyl, C _1-6 alkoxy C _1-6 alkyl, amino C _2-6 alkyl group, a sphere Or anininoC _2-6 alkyl group, mercaptoC _2-6 alkyl group, C _1-6 alkylthioC _1-6 alkyl group, aminocarbonylC _1-6 alkyl group, or R ⁶ and R ⁷ It may represent a group which forms a methylene group, an ethylene group, or a propylene group, may mutually combine, and may form a cyclic amino group, R <^8> represents a protecting group of a hydrogen atom or a carboxyl group, A represents a single bond, a methylene group, an ethylene group, or a propylene group Represents a natural or non-natural amino acid residue represented by
R ³ is C _1-10 acyl group, C _1-6 alkoxyC _1-6 acyl group, hydroxyC _2-10 acyl group, C _1-6 alkoxycarbonylC _1-6 acyl group, hydroxycarbonyl C An amino acid residue represented by _1-6 acyl group or R ⁹ -NH-A-CHR ⁷ -CO (wherein R ⁷ and A have the same meaning as described above and R ⁹ represents a protecting group of a hydrogen atom or an amino group) Indicate,
R ⁴ and R ⁵ are the same or different and a 5-membered heteroaromatic ring containing one or more hydrogen atoms, a C _1-10 alkyl group, a C _2-10 alkenyl group, a phenyl group, a naphthyl group, a hetero atom, or a halogen atom Substituted with 1 to 5 substituents selected from the group consisting of C _1-10 alkyl, C _1-10 alkoxy, trifluoromethyl, phenyl, hydroxycarbonyl, amino, nitro, cyano and phenoxy groups It may represent a phenyl group, or R ⁴ and R ⁵ may be bonded to each other to form a cyclic structure.
[18" claim-type="Currently amended] 18. A 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6 according to claim 17, wherein in formula (III), R ¹ and R ² are hydroxy and R ³ is a hydrogen atom. -Dicarboxylic acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[19" claim-type="Currently amended] The 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicar according to claim 17, wherein in formula (III), R ¹ is hydroxy and R ³ is a hydrogen atom. Acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[20" claim-type="Currently amended] 18. The 2-amino according to claim 17, wherein in formula (III), R ¹ is hydroxy, R ³ is a hydrogen atom, and R ² is a C _1-6 alkoxy group substituted with a C _1-10 alkoxy group or one phenyl group. 3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2.6-dicarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof.
[21" claim-type="Currently amended] 18. The ₂ -amino-3-alkoxy-6-fluorobicyclo of claim 17 wherein R ¹ is hydroxy, R ³ is a hydrogen atom, and R ² is NH-CHR ⁷ -CO ₂ H. [3.1.0] hexane-2,6-dicarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof.
[22" claim-type="Currently amended] 18. The 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicar according to claim 17, wherein in formula (III), R ² is hydroxy and R ³ is a hydrogen atom. Acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[23" claim-type="Currently amended] 18. A ² -amino compound according to claim 17, wherein in formula (III), R ² is hydroxy, R ³ is a hydrogen atom, and R ¹ is a C _1-6 alkoxy group substituted with a C _1-10 alkoxy group or one phenyl group. 3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof.
[24" claim-type="Currently amended] 18. The ₂ -amino-3-alkoxy-6-fluorobicyclo of claim 17 wherein R ² is hydroxy, R ³ is a hydrogen atom, and R ¹ is NH-CHR ⁷ -CO ₂ H. [3.1.0] hexane-2,6-dicarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof.
[25" claim-type="Currently amended] 18. The 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein R ¹ and R ² in formula III are hydroxy, Pharmaceutically acceptable salts or hydrates thereof.
[26" claim-type="Currently amended] 18. A 2-amino-3-alkoxy-6-fluorobicyclo [3.1.0] according to claim 17, wherein in formula (III), R ¹ and R ² are hydroxy and R ³ is NH ₂ -CHR ⁷ -CO. Hexane-2,6-dicarboxylic acid derivatives, pharmaceutically acceptable salts thereof or hydrates thereof.
[27" claim-type="Currently amended] A pharmaceutical formulation comprising one or two or more pharmaceutically acceptable carriers, excipients or diluents and a compound according to any one of claims 2 to 26.
[28" claim-type="Currently amended] A pharmaceutical comprising the compound according to any one of claims 2 to 26 as an active ingredient.
[29" claim-type="Currently amended] The pharmaceutical according to claim 28, which is a group II metabolic glutamic acid receptor antagonist.
[30" claim-type="Currently amended] Use of the compound according to any one of claims 2 to 26 as a medicament.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP4673833B2|2011-04-20|Macrocyclic β-secretase inhibitor for the treatment of Alzheimer&#39;s disease

---

US6956033B2|2005-10-18|3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient

---

KR100375463B1|2003-04-23|Synthetic exciting amino acids

---

JP4947406B2|2012-06-06|Compound having S1P receptor binding ability and pharmaceutical use thereof

---

CN1281274C|2006-10-25|6-fluorobicyclo 3.1.0 hexane derivatives

---

US8575134B2|2013-11-05|Aminocarboxylic acid derivative and medicinal use thereof

---

US6037362A|2000-03-14|Tricyclic compounds and drug compositions containing the same

---

KR100469182B1|2005-02-02|6-Fluorobicyclo[3.1.0]hexane Derivatives

---

EP1641748B1|2013-08-28|N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease

---

KR100618743B1|2006-08-31|Fused bicyclic or tricyclic amino acids

---

TWI445529B|2014-07-21|Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

---

ES2224604T3|2005-03-01|Bococñp | heptans and related compounds.

---

EP1280760B1|2004-04-28|Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof

---

US6071970A|2000-06-06|Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

---

JP5847088B2|2016-01-20|Acylamino substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals

---

US6469054B1|2002-10-22|Aryl sulphonamides and analogues

---

ES2461265T3|2014-05-19|Methyl-aryl or heteroaryl-amide substituted compounds

---

JP4494212B2|2010-06-30|Phenylcarboxamide beta-secretase inhibitor for the treatment of Alzheimer&#39;s disease

---

US20140051678A1|2014-02-20|Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases

---

US6545050B1|2003-04-08|Aryl sulphonamide amino acid esters and analogues

---

JP4071114B2|2008-04-02|Halogen-substituted aminodicarboxylic acid derivatives as drugs for treating cardiovascular diseases

---

US8609641B2|2013-12-17|-2-N-propylamino-5-hydroxytetralin as a D3-agonist

---

KR101581289B1|2015-12-31|Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors

---

US6710071B2|2004-03-23|Difluoromethylene aromatic ethers as inhibitors of glycine transport

---

US6846830B2|2005-01-25|Naphtalene derivatives and their pharmaceutical use

同族专利:

---

公开号 | 公开日

---

NZ533699A|2006-05-26|

---

EP1459765A4|2006-05-31|

---

HU228436B1|2013-03-28|

---

NO20042530D0|2004-06-16|

---

BR0215462A|2004-11-30|

---

DK1459765T3|2008-10-06|

---

ES2311642T3|2009-02-16|

---

NO328844B1|2010-05-25|

---

CA2471642C|2011-05-24|

---

EP1459765B1|2008-08-20|

---

HK1073258A1|2007-03-23|

---

CY1108380T1|2014-02-12|

---

ZA200502085B|2005-08-31|

---

EP1459765A1|2004-09-22|

---

RU2004122916A|2005-03-27|

---

DE60228491D1|2008-10-02|

---

AU2002359923B2|2007-12-20|

---

KR20090031962A|2009-03-30|

---

CN1610557A|2005-04-27|

---

PL371014A1|2005-06-13|

---

MXPA04006322A|2004-10-04|

---

US20050119345A1|2005-06-02|

---

PT1459765E|2008-10-03|

---

AT405289T|2008-09-15|

---

ZA200404795B|2005-08-31|

---

WO2003061698A1|2003-07-31|

---

SI1459765T1|2009-02-28|

---

RU2315622C2|2008-01-27|

---

JP4230919B2|2009-02-25|

---

JPWO2003061698A1|2005-05-19|

---

KR100897970B1|2009-05-18|

---

PL208123B1|2011-03-31|

---

US7157594B2|2007-01-02|

---

HU0402649A2|2005-10-28|

---

CN1281274C|2006-10-25|

---

CA2471642A1|2003-07-31|

---

NO20042530L|2004-09-22|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2001-12-27|Priority to JP2001395797

---

2001-12-27|Priority to JPJP-P-2001-00395797

---

2002-12-26|Application filed by 다이쇼 세이야꾸 가부시끼가이샤

---

2002-12-26|Priority to PCT/JP2002/013693

---

2004-07-30|Publication of KR20040068348A

---

2009-05-18|Application granted

---

2009-05-18|Publication of KR100897970B1

优先权:

---

申请号 | 申请日 | 专利标题

---

JP2001395797|2001-12-27|

---

JPJP-P-2001-00395797|2001-12-27|

---

PCT/JP2002/013693|WO2003061698A1|2001-12-27|2002-12-26|6-fluorobicyclo[3.1.0]hexane derivatives|